Nextcure, INC 8-K filings

NextCure, Inc. and Avere Therapeutics, Inc. have entered into a definitive merger agreement, combining Avere's oral IL-23 program with NextCure's public infrastructure, supported by a $320 million private placement.

NextCure stockholders approved an amendment to the 2019 Omnibus Incentive Plan, increasing authorized shares and updating evergreen provisions.

NextCure announced positive Phase 1 data for its investigational drug SIM0505 at ASCO 2026, showing a 55% ORR in gynecologic cancers.

NextCure, Inc. announced its full year 2025 financial results and provided updates on its clinical-stage antibody-drug conjugate programs, SIM0505 and LNCB74, with key data readouts anticipated in 2026.

NextCure, Inc. announced preliminary year-end 2025 cash of $41.8 million and provided updates on its SIM0505 and LNCB74 antibody drug conjugate programs, including a delay for LNCB74 proof-of-concept data.

NextCure, Inc. announced an at-the-market offering agreement to sell up to $14.5 million of common stock to fund general corporate purposes and advance product candidates.

NextCure, Inc. closed a $21.5 million private placement, extending its cash runway into the first half of 2027 to fund key ADC program data readouts.

NextCure, Inc. provided a business update on its ADC programs and reported third quarter 2025 financial results, highlighting progress in clinical trials and a reduced net loss.

NextCure, Inc. announced the resignation of Chief Scientific Officer Solomon Langermann, Ph.D., effective September 1, 2025.

NextCure reports Q2 2025 financial results, highlighting progress in its ADC pipeline, including a new strategic partnership and initial clinical activity for SIM0505.

NextCure, Inc. has completed a one-for-twelve reverse stock split of its common stock, effective July 14, 2025, following stockholder and board approval.

NextCure, Inc. has announced a one-for-twelve reverse stock split of its common stock, effective July 14, 2025, to consolidate shares and potentially meet exchange listing requirements.

NextCure, Inc. announced that its stockholders approved all key proposals at the 2025 Annual Meeting, including the election of three Class III directors, ratification of its accounting firm, executive compensation, and a crucial amendment for a potential reverse stock split.

NextCure, Inc. has entered into a strategic licensing agreement with Simcere Zaiming, gaining exclusive global rights to a clinical-stage antibody-drug conjugate (ADC) targeting CDH6, SIM0505, and access to proprietary ADC technology, alongside a $2.0 million private placement.

NextCure reports progress on its LNCB74 clinical trial and provides financial results for Q1 2025, with cash runway expected into the second half of 2026.

NextCure updates its corporate presentation to reflect progress on the ongoing clinical trial of LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4.

NextCure reports full year 2024 financial results, provides a business update, and anticipates funding operations into the second half of 2026.

NextCure, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

NextCure has announced the first patient has been dosed in a Phase 1 study of LNCB74, a B7-H4-targeting antibody-drug conjugate for treating multiple cancers.

NextCure has received FDA approval to begin a Phase 1 clinical trial for its cancer drug candidate, LNCB74, a B7-H4-targeting antibody-drug conjugate.

NextCure has filed an Investigational New Drug application for LNCB74, an antibody-drug conjugate targeting B7-H4, with first-in-human trials expected in Q1 2025.

NextCure is progressing its LNCB74 antibody-drug conjugate (ADC) program, targeting B7-H4 for breast, endometrial, and ovarian cancers, with an IND submission expected in Q4 2024 and proof-of-concept (POC) data anticipated in 2025.

NextCure is focusing its resources on the development of LNCB74, a B7-H4 ADC, with a planned IND submission by year-end, while seeking partners for other programs.

NextCure announced its second quarter 2024 financial results, highlighting progress in its clinical programs and a cash runway extending into the second half of 2026.

NextCure's 2024 Annual Meeting saw the election of two Class II directors, ratification of Ernst & Young as auditor, and the rejection of a proposal to exculpate company officers.

NextCure's Chief Medical Officer, Dr. Han Myint, will retire from his position on July 1, 2024, and transition to a consulting role, effective July 2, 2024, while continuing to vest in his existing equity awards.

NextCure announced its first quarter 2024 financial results and provided updates on its clinical programs, including upcoming data presentations and a planned IND submission.

NextCure is focusing on its NC410 and LNCB74 programs, restructuring operations, and extending its cash runway into the second half of 2026.